Latest posts tagged with #JITC on Bluesky
New Journal for ImmunoTherapy of Cancer position article and guidelines: "Spatial and phenotypic plasticity of B cells in remodeling the tumor microenvironment" https://jitc.bmj.com/content/14/3/e014745 #JITC #cancer 🧪
New Journal for ImmunoTherapy of Cancer position article and guidelines: "Spatial and phenotypic plasticity of B cells in remodeling the tumor microenvironment" jitc.bmj.com/content/14/3...
#JITC #cancer 🧪
New Journal for ImmunoTherapy of Cancer review: "γδ T cells at the interface of innate and adaptive immunity in cancer" https://jitc.bmj.com/content/14/3/e013668🧪 #JITC #cancer
New Journal for ImmunoTherapy of Cancer review: "γδ T cells at the interface of innate and adaptive immunity in cancer" jitc.bmj.com/content/14/3...
#JITC #cancer
New Journal for ImmunoTherapy of Cancer article: "Intratumoral PD-1-directed IL-2 expression via oncolytic vaccinia virus elicits superior antitumor effects with enhanced safety" https://jitc.bmj.com/content/14/3/e011340🧪
New Journal for ImmunoTherapy of Cancer article: "Intratumoral PD-1-directed IL-2 expression via oncolytic vaccinia virus elicits superior antitumor effects with enhanced safety" jitc.bmj.com/content/14/3...
#JITC #immunosky
New Journal for ImmunoTherapy of Cancer article: "Targeting endosomal trafficking-mediated antigen escape to resensitize myeloma to CAR-T therapy" jitc.bmj.com/content/14/3...
#JITC #research #ImmunoSky
New Journal for ImmunoTherapy of Cancer review: TCR sequencing in cancer immunology and immunotherapy: what, when, where, why, and how jitc.bmj.com/content/14/3...
#JITC #cancer
New Journal for ImmunoTherapy of Cancer article: Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinoma jitc.bmj.com/content/14/3...
#JITC #research
New Journal for ImmunoTherapy of Cancer Commentary on “Comparative efficacy and safety of PSCA CAR-engineered Vδ1 γδ T cells for immunotherapy of pancreatic cancer
jitc.bmj.com/content/14/2...
#JITC #cancer
New Journal for ImmunoTherapy of Cancer review: Unlocking the promise of innate biology through the HLA-G/ILT2/ILT4 pathway https://jitc.bmj.com/content/14/2/e013313 @jasonlukemd.bsky.social #JITC #cancer #research #ImmunoSky 🧪
New Journal for ImmunoTherapy of Cancer review: Unlocking the promise of innate biology through the HLA-G/ILT2/ILT4 pathway jitc.bmj.com/content/14/2...
@jasonlukemd.bsky.social
#JITC #cancer #research #ImmunoSky 🧪
In honor of National #CancerPreventionMonth, the Feb. Issue of the #JITC Digest features a commentary from Dr. Olja Finn focused on the global need to prevent cancer. Explore her expert analysis and access cutting-edge articles on evolving biomarkers: https://ow.ly/yqFG50YhIl0
New Journal for ImmunoTherapy of Cancer article: Oral immunization with Listeria monocytogenes vaccine enhances immunotherapy for protective immunity in murine models of colorectal cancer jitc.bmj.com/content/14/2...
#JITC #cancer
New Journal for ImmunoTherapy of Cancer article: Targeting RRBP1 reverses immune evasion and enhances immunotherapy efficacy via the CXCL10-CXCR3 axis in bladder cancer
jitc.bmj.com/content/14/2...
#JITC #MedSky
New Journal for ImmunoTherapy of Cancer article: MMP3 overexpression enhances CAR-T cell infiltration and antitumor activity in a CAF-enriched solid tumor model https://jitc.bmj.com/content/14/1/e013211 #JITC #MedSky 🧪
New Journal for ImmunoTherapy of Cancer article: MMP3 overexpression enhances CAR-T cell infiltration and antitumor activity in a CAF-enriched solid tumor model jitc.bmj.com/content/14/1...
#JITC #MedSky 🧪
New Journal for ImmunoTherapy of Cancer article: Non-superagonist CD28-based dual-signal T cell engager targeting https://jitc.bmj.com/content/14/1/e013246 #JITC #ImmunoSky🧪
New Journal for ImmunoTherapy of Cancer article: Non-superagonist CD28-based dual-signal T cell engager targeting jitc.bmj.com/content/14/1...
#JITC #ImmunoSky🧪
The January issue of the #JITC Digest features highlighted manuscripts examining gastrointestinal malignancies, along with key insights from Dr. Kimryn Rathmell’s plenary address at the #ASCO Gastrointestinal Cancers Symposium. Read the issue: https://ow.ly/luZq50Y0Jqx
Screenshot of new commentary by Dr. Olja Finn from the University of Pittsburgh Department of Immunology titled "Opportunity knocking: shared tumor-associated antigen vaccines against global cancer pandemic."
In a new @sitcancer.bsky.social #JITC commentary, Dr. Olja Finn makes the case that tumor-associated antigen vaccines, which failed as monotherapies, should be reconsidered as combination therapies with checkpoint inhibitor #immunotherapy for the treatment and prevention of #cancer.
New Journal for ImmunoTherapy of Cancer case report: Intratumoral dendritic cell immunotherapy controls dissemination of metastasis-initiating cancer cells, even in patients with metastatic breast cancer jitc.bmj.com/content/14/1...
#JITC #MedSky
New Journal for ImmunoTherapy of Cancer article: Single-cell and spatial transcriptome profiling identifies the immunosuppressive spatial niche in KRAS-mutant colorectal cancer https://t.co/D0t9Fj2UAm #JITC #MedSky #ImmunoSky 🧪
New Journal for ImmunoTherapy of Cancer article: Single-cell and spatial transcriptome profiling identifies the immunosuppressive spatial niche in KRAS-mutant colorectal cancer t.co/D0t9Fj2UAm
#JITC #MedSky #ImmunoSky 🧪
New Journal for ImmunoTherapy of Cancer review: Cytotoxic CD4+ T cells in cancer: an emerging target for next-generation anticancer immunotherapy? t.co/kFxqcpVxOS
#JITC #ImmunoSky
New Journal for ImmunoTherapy of Cancer article: In situ DC-primed vaccine combined with CD137 agonist elicits long-lasting antitumor immunity through cDC1-mediated tumor antigen-specific CD8+ T cell responses https://t.co/MH5lQvHMLw 🧪 #JITC #MedSky #ImmunoSky
New Journal for ImmunoTherapy of Cancer article: In situ DC-primed vaccine combined with CD137 agonist elicits long-lasting antitumor immunity through cDC1-mediated tumor antigen-specific CD8+ T cell responses t.co/MH5lQvHMLw 🧪
#JITC #MedSky #ImmunoSky
In the December #JITC Digest, Editor-in-Chief Dr. Michael Lotze highlights the latest developments and emerging trends in cancer immunotherapy. This month's selection of manuscripts features a fundamental focus on mechanisms of IO involving Tregs. Read the Dec. Issue: https://ow.ly/mwub50XL4o4
New Journal for ImmoTherapy of Cancer article: Colorectal cancer organoids drive hypoxia, TGF-β, and patient-specific diversification of NK cell activation programs t.co/QTd6A59Ul5
#JITC #ImmunoSky
As Fangling Ning presents data on SIRpα-fc fusion protein at #ESMOImmuno25, address blockade of CD47 with this recent #JITC article from Chilam Chan et al of UMC Utrecht: https://ow.ly/lbJV50XH7A5
As Dimitrios A. Garyfallos shares new findings on, “In vivo CRISPR/Cas9 genetic screens identify novel immunotherapy target” at #ESMOImmuno25, discover more on CRISPR with #JITC!
New Journal for ImmunoTherapy of Cancer article: Neutrophil extracellular traps–STC1 positive feedback loop promotes immune evasion and metastasis in bladder cancer jitc.bmj.com/content/13/1...
#JITC #MedSky
New Journal for ImmunoTherapy of Cancer article: Engineering TME-activated CD47-specific CAR macrophage via Arg1 promoter for safe and effective solid tumor immunotherapy
t.co/xYSEvcRGST
#JITC #ImmunoSky
🚀 just published @sitcancer.bsky.social #JITC
👥 34,973 pts
♻️ 47 #RCT
💉 PD-1 the earlier the better
HR=0.74
📌 #PFS2 great correlation to #OS
R² 0.74 #PFS2 vs 0.39 #PFS
Led by Dr. Jimenez-Labaig
@oncoalert.bsky.social @brunolarvol.bsky.social @vhio.bsky.social
👇🏽
jitc.bmj.com/content/jitc/1…
In the Nov. Issue of the #JITC Digest, Editor-in-Chief Dr. Michael T. Lotze reflects on his experience at #SITC25 and several recent IO meetings. Explore his curated selection of cutting-edge articles, including new insights on LAG-3 blockade and more. View the Nov. Issue: https://ow.ly/fTO150Xun1R
New Journal for ImmunoTherapy of Cancer review: Myeloid metabolism and its role in immunotherapy of cancer https://jitc.bmj.com/content/13/11/e012127 #JITC #MedSky 🧪
New Journal for ImmunoTherapy of Cancer review: Myeloid metabolism and its role in immunotherapy of cancer jitc.bmj.com/content/13/1...
#JITC #MedSky 🧪
New Journal for ImmunoTherapy of Cancer review: Chimeric antigen receptor (CAR) T-cell therapy for glioblastoma (GBM): current clinical insights, challenges, and future directions https://jitc.bmj.com/content/13/10/e012308 #JITC #ImmunoSky 🧪
New Journal for ImmunoTherapy of Cancer review: Chimeric antigen receptor (CAR) T-cell therapy for glioblastoma (GBM): current clinical insights, challenges, and future directions jitc.bmj.com/content/13/1...
#JITC #ImmunoSky 🧪
